Sean Baker, DO
Family Medicine · Fort Smith, ARNPI 1508060641
Payments from drug & device makers
Across 166 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$488
- Amgen$311
- Novo Nordisk$180
- AstraZeneca$178
- Abbott$166
- GSK$142
- plus $959 from 20 others
What the payments were for
- Food & beverage$2,417100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 36 | $488 |
| Amgen | 20 | $311 |
| Novo Nordisk | 11 | $180 |
| AstraZeneca | 12 | $178 |
| Abbott | 10 | $166 |
| GSK | 10 | $142 |
| Pfizer | 10 | $141 |
| Sanofi-aventis U.S. LLC | 12 | $125 |
| Astellas Pharma US Inc | 6 | $87 |
| Novartis | 5 | $74 |
| Merck | 4 | $69 |
| Boehringer Ingelheim | 5 | $65 |
| Johnson & Johnson | 4 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Amarin Pharma, Inc. | 3 | $50 |
| Acclarent, Inc | 1 | $40 |
| Lilly USA, LLC | 2 | $27 |
| Supernus Pharmaceuticals, Inc. | 2 | $25 |
| Sanofi Pasteur Inc. | 2 | $25 |
| Sumitomo Pharma America, Inc. | 2 | $23 |
| Corium, LLC | 1 | $20 |
| Radius Health, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Boston Scientific | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$2,423 in reported general payments places this provider in the 75th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 154 | $147,368 |
| OzempicSemaglutide | 59 | $88,421 |
| EliquisApixaban | 89 | $86,106 |
| MounjaroTirzepatide | 51 | $64,703 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $56,656 |
| TrulicityDulaglutide | 45 | $56,158 |
| FarxigaDapagliflozin Propanediol | 46 | $54,157 |
| MyrbetriqMirabegron | 64 | $49,189 |
| XifaxanRifaximin | 12 | $35,641 |
| Repatha SureclickEvolocumab | 55 | $30,718 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $29,223 |
| JanuviaSitagliptin Phosphate | 14 | $22,899 |
| XareltoRivaroxaban | 18 | $18,145 |
| LinzessLinaclotide | 12 | $12,412 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 82 | $11,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $65 | $147,368154 claims |
| Lilly USA, LLCMounjaro, Trulicity | $27 | $120,86196 claims |
| Novo NordiskOzempic | $180 | $88,42159 claims |
| PfizerEliquis | $141 | $86,10689 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $142 | $66,43797 claims |
| AstraZenecaFarxiga, Symbicort | $178 | $57,79660 claims |
| Astellas Pharma US IncMyrbetriq | $87 | $49,18964 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $13 | $35,64112 claims |
| MerckJanuvia | $69 | $22,89914 claims |
| Johnson & JohnsonXarelto | $54 | $18,14518 claims |
| AbbVieLinzess | $488 | $12,41212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Fort Smith
- Glenn GibbonsFort Smith$179K
- Thinh NguyenFort Smith$28K
- Allen BeachyFort Smith$21K
- Michael CallawayFort Smith$15K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.